The Health Care Crisis of the Century
By Alex Daley, Chief Technology Investment Strategist, Casey Research
As the American population ages, a pressing healthcare crisis is unfolding. The surge in individuals aged 65 and older is significant, driven primarily by the aging baby boomer generation. While this demographic shift reflects improved longevity and health in older adulthood, it also brings challenges, particularly concerning serious illnesses that detract from quality of life.
One such illness is Alzheimer’s disease, the most prevalent type of dementia. Identified over a century ago by Dr. Alois Alzheimer, the medical community still grapples with uncertainties regarding its causes and mechanisms. The upward trend in Alzheimer’s cases parallels our aging society, with current estimates indicating that around 5.2 million Americans are affected. This figure is expected to surpass 11 million within the next 26 years, as highlighted by the 2013 Alzheimer’s Association report.
Consider the staggering healthcare costs associated with this condition:
- In 2013, the direct costs of Alzheimer’s care amounted to approximately $203 billion, with $142 billion covered by taxpayer-funded Medicare and Medicaid.
- By 2050, the total expenditures for healthcare, long-term care, and hospice services for Alzheimer’s patients are projected to rise to $1.2 trillion.
- This increase represents a staggering 500 percent surge in combined Medicare and Medicaid spending.
This escalating crisis is not only a result of rising cases but also a looming burden on a healthcare system already under stress.
Is There Hope for a Cure?
Historically, research on Alzheimer’s has been slow, leaving scientists with limited understanding of its specific causes. Until recently, the prevailing theory posited a mix of genetic, environmental, and lifestyle contributions to the disease, without reliable biomarkers to identify those at risk or effective treatments.
Pharmaceutical companies have managed to develop medications that may slow disease progression, but these are not effective long-term solutions. Currently, there are only five FDA-approved drugs for Alzheimer’s, none of which demonstrate significant effectiveness. Consumer Reports Health starkly states that most individuals using these medications are unlikely to experience meaningful benefits compared to a placebo.
The Alzheimer’s Association indicates that, on average, these approved drugs provide benefits for only six to twelve months and affect approximately half of the users positively. Nevertheless, the potential for a breakthrough in treatment is on the horizon, with one small company emerging as a front-runner in developing innovative solutions.
Exploring Metallic Catalysts
Alzheimer’s disease hampers communication between neurons in the brain, leading ultimately to neuronal death and impairment of memory and cognitive abilities. Researchers are making strides toward understanding the disease, especially the role of beta-amyloid plaques that accumulate in the brain and their correlation with chronic infections, such as gingivitis. Notably, the interaction between these plaques and essential biological metals like zinc and copper may lead to neuronal damage.
Previously considered primary culprits in neuronal damage, more researchers now posit that smaller, soluble beta-amyloid oligomers, which are found in synapses, might be the real offenders. These oligomers disrupt communication between neurons by interfering with metal interactions, resulting in a loss of information transmission and subsequent neuronal death due to inactivity.
A promising biotech startup is working on compounds aimed at neutralizing these biological metals, preventing the disruption of neuronal communication and potentially allowing the brain to heal. The company is approaching a major milestone: a trial that could confirm the effectiveness of its approach in human subjects, following encouraging animal testing and anecdotal evidence from initial human trials.
As interest in this enterprise grows, its valuation has soared—going from a $30 million market cap to significant increases after positive study results, including findings related to Huntington’s disease. Investment firm Deutsche Bank estimates the global Alzheimer’s drug market could be worth $20 billion annually, and this company might capture a significant share of that market.
Even a conservative revenue projection of $1 billion annually could dramatically elevate its share value compared to similar firms in the sector. While much of the optimism may already be reflected in the current share price, a forthcoming positive trial outcome could yield substantial financial returns for investors pending its progress toward market readiness.
Click here to learn more about this potential breakthrough in Alzheimer’s treatment and the investment opportunities it presents.
Sincerely,
Alex Daley
for Economic Prism
[Editor’s Note: Alex Daley is the senior editor of Casey’s Extraordinary Technology. With an extensive background in technology and investment, he has been closely involved with numerous startups, providing insights to industry leaders and angel investors. The article The Healthcare Crisis of the Century was originally published at caseyresearch.com.]
Return from The Health Care Crisis of the Century to Economic Prism
